803 related articles for article (PubMed ID: 23087408)
21. Targeting immune checkpoints in lymphoma.
Ansell SM
Curr Opin Hematol; 2015 Jul; 22(4):337-42. PubMed ID: 26049755
[TBL] [Abstract][Full Text] [Related]
22. Are there, or shall we discover, biomarkers to guide PD-1 inhibition?
Ascierto PA; de Mello RA
Immunotherapy; 2016 Jun; 8(6):681-6. PubMed ID: 27197537
[TBL] [Abstract][Full Text] [Related]
23. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
Shin DS; Ribas A
Curr Opin Immunol; 2015 Apr; 33():23-35. PubMed ID: 25621841
[TBL] [Abstract][Full Text] [Related]
24. Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma.
Cheah CY; Fowler NH; Neelapu SS
Curr Opin Oncol; 2015 Sep; 27(5):384-91. PubMed ID: 26248256
[TBL] [Abstract][Full Text] [Related]
25. The PD-1/PD-L1 axis in the pathogenesis of urothelial bladder cancer and evaluating its potential as a therapeutic target.
Bardoli AD; Afshar M; Viney R; Foster M; Porfiri E; Zarkar A; Stevenson R; James ND; Bryan RT; Patel P
Future Oncol; 2016 Mar; 12(5):595-600. PubMed ID: 26880382
[No Abstract] [Full Text] [Related]
26. Is PD-L1 Expression a Biomarker of Response?
Colwell J
Cancer Discov; 2015 Dec; 5(12):1232. PubMed ID: 26516064
[TBL] [Abstract][Full Text] [Related]
27. The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy.
Muenst S; Soysal SD; Tzankov A; Hoeller S
Expert Opin Ther Targets; 2015 Feb; 19(2):201-11. PubMed ID: 25491730
[TBL] [Abstract][Full Text] [Related]
28. PD-1/PD-L1 inhibitors.
Sunshine J; Taube JM
Curr Opin Pharmacol; 2015 Aug; 23():32-8. PubMed ID: 26047524
[TBL] [Abstract][Full Text] [Related]
29. Antagonists of PD-1 and PD-L1 in Cancer Treatment.
Lipson EJ; Forde PM; Hammers HJ; Emens LA; Taube JM; Topalian SL
Semin Oncol; 2015 Aug; 42(4):587-600. PubMed ID: 26320063
[TBL] [Abstract][Full Text] [Related]
30. Inhibitors of programmed cell death 1 (PD-1): a patent review (2010-2015).
Zarganes-Tzitzikas T; Konstantinidou M; Gao Y; Krzemien D; Zak K; Dubin G; Holak TA; Dömling A
Expert Opin Ther Pat; 2016 Sep; 26(9):973-7. PubMed ID: 27367741
[No Abstract] [Full Text] [Related]
31. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.
Lu J; Lee-Gabel L; Nadeau MC; Ferencz TM; Soefje SA
J Oncol Pharm Pract; 2015 Dec; 21(6):451-67. PubMed ID: 24917416
[TBL] [Abstract][Full Text] [Related]
32. Combination cancer immunotherapy and new immunomodulatory targets.
Mahoney KM; Rennert PD; Freeman GJ
Nat Rev Drug Discov; 2015 Aug; 14(8):561-84. PubMed ID: 26228759
[TBL] [Abstract][Full Text] [Related]
33. Overcoming T cell exhaustion in infection and cancer.
Pauken KE; Wherry EJ
Trends Immunol; 2015 Apr; 36(4):265-76. PubMed ID: 25797516
[TBL] [Abstract][Full Text] [Related]
34. Immune Checkpoint Therapies in Prostate Cancer.
Goswami S; Aparicio A; Subudhi SK
Cancer J; 2016; 22(2):117-20. PubMed ID: 27111907
[TBL] [Abstract][Full Text] [Related]
35. [The Role of PD-1/PD-L1 Signaling Pathway in Antitumor Immune Response].
Zatloukalová P; Pjechová M; Babčanová S; Hupp TR; Vojtěšek B
Klin Onkol; 2016; 29 Suppl 4(Suppl 4):72-77. PubMed ID: 27846724
[TBL] [Abstract][Full Text] [Related]
36. Programmed death-1 inhibition in renal cell carcinoma: clinical insights and future directions.
Pal SK; Hu A; Chang M; Figlin RA
Clin Adv Hematol Oncol; 2014 Feb; 12(2):90-9. PubMed ID: 24892254
[TBL] [Abstract][Full Text] [Related]
37. The State of Immune Checkpoint Inhibition in Urothelial Carcinoma: Current Evidence and Future Areas of Exploration.
Campbell MT; Siefker-Radtke AO; Gao J
Cancer J; 2016; 22(2):96-100. PubMed ID: 27111904
[TBL] [Abstract][Full Text] [Related]
38. Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC.
Jørgensen JT
Expert Rev Mol Diagn; 2016; 16(2):131-3. PubMed ID: 26559787
[TBL] [Abstract][Full Text] [Related]
39. HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade.
Woods DM; Sodré AL; Villagra A; Sarnaik A; Sotomayor EM; Weber J
Cancer Immunol Res; 2015 Dec; 3(12):1375-85. PubMed ID: 26297712
[TBL] [Abstract][Full Text] [Related]
40. Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma.
Loo K; Daud A
Immunotherapy; 2016 Jun; 8(7):775-84. PubMed ID: 27349977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]